In a single-center retrospective study involving 109 patients diagnosed with PSCC and treated with surgical resection, HPV p16 positivity predicted a 2-year locoregional control benefit over HPV p16 negativity when subsequently treated with adjuvant chemoradiotherapy [79]. This evidence concerns the gene CDKN2A and squamous cell carcinoma of penis.